Insider · CIK 0001352546
James E Flynn
ownerdirectorother
Files at LRMR (Larimar Therapeutics, Inc.), AFIB (Acutus Medical, Inc.), SPRY (ARS Pharmaceuticals, Inc.), HLSQ (BiomX Inc.), NUVL (Nuvalent, Inc.). First filing Oct 24, 2024, latest Aug 4, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 3
$30M bought, $219M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRY: ARS Pharmaceuticals, Inc.
SPRYOct 9, 2026 · close 4.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | LRMRbuy Larimar Therapeutics, Inc. | $30M 9,375,000 shares | +152% | - | |
| 50Moderate | ARS Pharmaceuticals, Inc. | $14M 740,149 shares | -14% | +79% from low0% from high | |
| 57Moderate | ARS Pharmaceuticals, Inc. | $10M 563,270 shares | -10% | - | |
| 60Notable | Nuvalent, Inc. | $196M 2,000,000 shares | -21% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2025 | LRMR Larimar Therapeutics, Inc. | POpen-market purchase Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | +3,387,529 | $3.20 | $11M | 9,538,918 | Aug 4, 2025 |
| Jul 31, 2025 | LRMR Larimar Therapeutics, Inc. | POpen-market purchase Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | +3,387,539 | $3.20 | $11M | 9,538,945 | Aug 4, 2025 |
| Jul 31, 2025 | LRMR Larimar Therapeutics, Inc. | POpen-market purchase Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P. | +2,599,932 | $3.20 | $8.3M | 7,321,129 | Aug 4, 2025 |
| Jun 27, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -370,075 | $18.46 | $6.8M | 4,887,254 | Jul 1, 2025 |
| Jun 27, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -370,074 | $18.46 | $6.8M | 4,887,254 | Jul 1, 2025 |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stockindirect: Through Deerfield Management Company, L.P. | +2,647 | $0.00 | $0 | 2,647 | Jun 20, 2025 |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stockindirect: Through Deerfield Management Company, L.P. | +2,647 | $0.00 | $0 | 2,647 | Jun 20, 2025 |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: Through Deerfield Management Company, L.P. | +4,147 | $0.00 | $0 | 4,147 | Jun 20, 2025 |
| Jun 18, 2025 | NUVL Nuvalent, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: Through Deerfield Management Company, L.P. | +4,147 | $0.00 | $0 | 4,147 | Jun 20, 2025 |
| May 13, 2025 | LRMR Larimar Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: Through Deerfield Management Company, L.P. | +19,000 | $0.00 | $0 | 19,000 | May 15, 2025 |
| Apr 21, 2025 | HLSQ BiomX Inc. | AGrant or award Warrantsderivativeindirect: Through Deerfield Private Design Fund V, L.P. | +1,611,864 | - | - | 1,611,864 | Apr 23, 2025 |
| Apr 21, 2025 | HLSQ BiomX Inc. | AGrant or award Warrantsderivativeindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | +1,611,864 | - | - | 1,611,864 | Apr 23, 2025 |
| Apr 14, 2025 | HLSQ BiomX Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: Through Deerfield Management Company, L.P. | +17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Feb 27, 2025 | HLSQ BiomX Inc. | MOption exercise Common Stockindirect: Through Deerfield Private Design Fund V, L.P. | +353,249 | $0.93 | $329k | 1,247,054 | Mar 3, 2025 |
| Feb 27, 2025 | HLSQ BiomX Inc. | MOption exercise Common Stockindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | +353,249 | $0.93 | $329k | 1,247,054 | Mar 3, 2025 |
| Feb 27, 2025 | HLSQ BiomX Inc. | MOption exercise Warrantsderivativeindirect: Through Deerfield Private Design Fund V, L.P. | -1,611,863 | - | - | 405,637 | Mar 3, 2025 |
| Feb 27, 2025 | HLSQ BiomX Inc. | MOption exercise Warrantsderivativeindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | -1,611,863 | - | - | 405,637 | Mar 3, 2025 |
| Feb 27, 2025 | HLSQ BiomX Inc. | AGrant or award Warrantsderivativeindirect: Through Deerfield Private Design Fund V, L.P. | +1,258,614 | - | - | 1,258,614 | Mar 3, 2025 |
| Feb 27, 2025 | HLSQ BiomX Inc. | AGrant or award Warrantsderivativeindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | +1,258,614 | - | - | 1,258,614 | Mar 3, 2025 |
| Jan 27, 2025 | AFIB Acutus Medical, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivativeindirect: Through Deerfield Partners, L.P. | -1,889,509 | - | - | 0 | Jan 28, 2025 |
| Jan 27, 2025 | AFIB Acutus Medical, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivativeindirect: Through Deerfield Private Design Fund III, L.P. | -1,889,509 | - | - | 0 | Jan 28, 2025 |
| Jan 27, 2025 | AFIB Acutus Medical, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivativeindirect: Through Deerfield Private Design Fund III, L.P. | -209,996 | - | - | 0 | Jan 28, 2025 |
| Jan 27, 2025 | AFIB Acutus Medical, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivativeindirect: Through Deerfield Private Design Fund III, L.P. | -193,002 | - | - | 0 | Jan 28, 2025 |
| Jan 27, 2025 | AFIB Acutus Medical, Inc. | DDisposition to issuer Warrant to Purchase Common Stockderivativeindirect: Through Deerfield Partners, L.P. | -31,116 | - | - | 0 | Jan 28, 2025 |
| Nov 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -40,596 | $17.45 | $708k | 5,498,368 | Nov 13, 2024 |
| Nov 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -40,596 | $17.45 | $708k | 5,498,367 | Nov 13, 2024 |
| Nov 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -223,632 | $18.15 | $4.1M | 5,274,736 | Nov 13, 2024 |
| Nov 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -223,632 | $18.15 | $4.1M | 5,274,735 | Nov 13, 2024 |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -7,853 | $17.16 | $135k | 5,266,883 | Nov 13, 2024 |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -7,854 | $17.16 | $135k | 5,266,881 | Nov 13, 2024 |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund III, L.P. | -9,554 | $17.77 | $170k | 5,257,329 | Nov 13, 2024 |
| Nov 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -9,553 | $17.77 | $170k | 5,257,328 | Nov 13, 2024 |
| Oct 22, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Private Design Fund IV, L.P. | -1,000,000 | $97.75 | $98M | 8,670,512 | Oct 24, 2024 |
| Oct 22, 2024 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stockindirect: Through Deerfield Healthcare Innovations Fund, L.P. | -1,000,000 | $97.75 | $98M | 8,670,512 | Oct 24, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.